Clinical trials: Hematopoietic Stem Cells
Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed)…
- Conditions
- Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma, T Lymphoblastic Lymphoma
- Trial name
- NCT04315324
- Testing
- AKR1C3-activated Prodrug AST-3424, Biopsy Procedure, Biospecimen Collection
- Where
- 163 sites in United States
- Volunteers
- 67 people
- Sponsor
- SWOG Cancer Research Network
Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
This phase I trial is studying the side effects and best dose of veliparib when given together with topotecan hydrochloride with or without carboplatin in treating patients with relapsed or refractory acute leukemia, high-risk…
- Conditions
- Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- Trial name
- NCT00588991
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Topotecan Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Acute Leukemia
Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT)
This is a single-center, single-arm, prospective exploratory study designed to evaluate the safety and efficacy of luspatercept for the treatment of anemia following allogeneic hematopoietic stem cell transplantation in patients…
- Trial name
- Allo-HSCT (NCT07362095)
- Testing
- Luspatercept
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Zhujiang Hospital
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
This is a non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01. Up to 12 subjects who completed ApoGraft-01 study will be offered to participate in this follow-up study.
- Conditions
- Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Non Hodgkin Lymphoma (NHL), Hodgkin Lymphoma, Adult
- Trial name
- NCT03260101
- Testing
- non intervational
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Cellect Biotechnology
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
The Patient Cohort of the National Center for Precision Medicine in Leukemia
If for years the treatment strategy of leukemia and related disorders (LRDs, including acute leukemias and predisposition syndromes) has been based solely on whether the patient could receive or not intensive chemotherapy and…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome, Secondary Myelofibrosis in Myeloproliferative Disease
- Trial name
- eTHEMA (NCT05326919)
- Testing
- Biobanking
- Where
- 3 sites in France
- Volunteers
- 3,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Leukemia
Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia
RATIONALE: Diagnostic procedures, such as genetic testing, may improve the ability to detect acute lymphocytic leukemia and determine the extent of disease.
- Trial name
- NCT00003933
- Testing
- laboratory biomarker analysis
- Where
- 41 sites in United States, Australia and 1 more
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
This is a prospective, multicenter, randomized controlled trial designed to evaluate the efficacy and safety of venetoclax-enhanced BUCY (Ven-BUCY) conditioning compared to the standard BUCY regimen in patients with high-risk…
- Conditions
- Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndromes, High-Risk Myelodysplastic Syndromes
- Trial name
- Ven-BUCY (NCT07183878)
- Testing
- Venetoclax, Busulfan (BU)
- Where
- China
- Volunteers
- 138 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Leukemia, Lymphoblastic, Acute, ALL, Childhood
Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology Branch
Background: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. It occurs when a bone marrow cell develops errors in its DNA. Certain tests are used to help detect the disease.
- Trial name
- NCT03627208
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
CD19-chimeric Antigen Receptor T Cells, Relapsed and/or Refractory Acute Lymphoblastic Leukemia
Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation
Building a new haploid transplanted model with high-dose CTX、CD19-CART,donor CD34+ hematopoietic stem cell and Tregs,to prevent graft-versus-host disease(GVHD),reduce the infection,promote the rate of immune…
- Conditions
- CD19-chimeric Antigen Receptor T Cells, Relapsed and/or Refractory Acute Lymphoblastic Leukemia, the Haploidentical Hematopoietic Stem Cell Transplantation
- Trial name
- NCT03423706
- Testing
- the new model of haplo-HSCT for r/r B-ALL
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Trauma, Appendectomy
Hospital Based Continuous Patient Monitoring System
In Ghana, and many other low and middle income countries in Africa, manual vital signs monitoring is the prevalent mode of vital signs monitoring because continuous bedside monitors are non-functional.
- Conditions
- Trauma, Appendectomy, Pediatric ALL, Vital Signs Monitoring
- Trial name
- NCT06739447
- Testing
- Consumer Wearable Device Vital Sign Measurement
- Where
- Ghana
- Volunteers
- 250 people
- Sponsor
- University of Alabama at Birmingham
Bronchiolitis Obliterans Syndrome
Novel Pulmonary Function Measures for Diagnosis of Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem-Cell Transplantation in Children
In this study, we will study 129Xe-MRI and LCI as tools for diagnosis of BOS in pediatric patients who have received Hematopoietic Stem Cell Transplantation (HSCT) and have been identified as eligible for this study.
- Trial name
- NCT04391335
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- The Hospital for Sick Children
Hematopoietic Cell Transplant
The MedMemos Study: Promoting Adherence to Medications in Pediatric Bone Marrow Transplant Patients
The goal of this clinical trial is to test the MedMemos Intervention with parents and children who have received a bone marrow transplant.
- Trial name
- MedMemos (NCT07718204)
- Testing
- MedMemos
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Nationwide Children's Hospital
Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection
Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)
HLH, HLH-related disorders, Chronic Granulomatous (CGD), HIGM1, Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX) and severe LAD-I represent primary immune disorders that are typically fatal…
- Conditions
- Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection, Chronic Granulomatous Disease, HIGM-1
- Trial name
- RICHI (NCT01998633)
- Testing
- Hematopoietic Stem Cell Transplant
- Where
- 22 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Medical College of Wisconsin
Hematologic Neoplasm, HIV Infection
Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer
This study will investigate the safety and effectiveness of a new stem cell transplant procedure to treat acute or chronic leukemia, multiple myeloma, myelodysplastic syndrome, Hodgkin's and non-Hodgkin's lymphoma in HIV-infected…
- Trial name
- NCT00005785
- Testing
- GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
the Efficacy and Safety of CLAE in R/R T-ALL/LBL
To evaluate the efficacy and safety of CLAE regimen (cladribine + cytarabine + etoposide) in the treatment of relapsed/refractory T-ALL/LBL.
- Trial name
- NCT04679506
- Testing
- Cladribine
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
Hematopoietic Stem Cell Transplantation (HSCT)
Prehabilitation to Improve Frailty, Function, and Quality of Life in Candidates for Hematopoietic Stem Cell Transplantation
Candidates for hematopoietic stem cell transplantation (HSCT) frequently experience declines in strength, physical function, and quality of life before the procedure.
- Trial name
- PREHAB-HSCT (NCT07255521)
- Testing
- Multimodal Prehabilitation
- Where
- 2 sites in Chile
- Volunteers
- 68 people
- Sponsor
- Hospital del Salvador
Peripheral T Cell Lymphoma
A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
This study is a single-center, single-arm, prospective, phase II clinical trial designed to evaluate the efficacy and safety of Cidabenamine combined with Azacitidine as maintenance therapy following allogeneic peripheral blood…
- Trial name
- NCT07389616
- Testing
- Cidabenamine, Azacitidine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hematologic Neoplasms
Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units
The administration of high-dose chemotherapy followed by the infusion of blood or bone marrow stem cells (stem cell transplantation) from a matched donor has become standard treatment for patients with high-risk or relapsed…
- Trial name
- NCT02504047
- Testing
- T-Cell replete haplo-transplant
- Where
- 5 sites in Canada
- Volunteers
- 40 people
- Sponsor
- University of Calgary
Acute Lymphoid Leukemia
Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia
This is a multi-center, phase 2A exploratory study of feasibility and effectiveness of Inotuzumab Ozagomicin in adult patients with Acute Lymphoid Leukemia (ALL) with positive minimal residual disease before any hematopoietic…
- Trial name
- ALL2418 (NCT03610438)
- Testing
- Inotuzumab Ozogamicin (IO)
- Where
- 30 sites in Italy
- Volunteers
- 76 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
This phase II trial is studying the side effects and how well giving fludarabine phosphate, busulfan, anti-thymocyte globulin followed by donor peripheral blood stem cell transplant, tacrolimus, and methotrexate works in treating…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01056614
- Testing
- fludarabine phosphate, busulfan, anti-thymocyte globulin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.